文献速递头颈部肿瘤放疗

基于鼻咽癌逐步扩散模式的临床靶区个体化勾画:十余年临床经验的结果

Individualization of Clinical Target Volume Delineation Based on Stepwise Spread of Nasopharyngeal Carcinoma: Outcome of More Than a Decade of Clinical Experience.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-10-15

该研究回顾性评估了1999至2013年73例接受根治性放疗的非转移性鼻咽癌患者,采用基于个体肿瘤范围和有序逐步扩散模式的临床靶区勾画技术。中位随访90个月,5年局部控制率94%、区域控制率99%、总生存率84%,所有局部区域复发均位于高剂量大体肿瘤体积内。与HN001方案相比,该勾画策略使T1和T4期临床靶区体积分别减少62%和36%。

要点

  • 基于逐步扩散模式的个体化临床靶区勾画获得良好的局部控制,无大体肿瘤体积外复发
  • 与HN001方案相比,T1期临床靶区体积减少62%,T4期减少36%
  • 无2级及以上口干,无4/5级毒性,仅10例3级毒性

核心结论

  • 基于逐步扩散模式的个体化临床靶区勾画长期经验显示良好的局部控制,无大体肿瘤体积外复发。

研究设计与样本

  • 回顾性评估1999年至2013年73例新诊断非转移性鼻咽癌患者,接受根治性放疗,采用基于个体肿瘤范围和有序逐步扩散模式的临床靶区勾画技术。
  • 对代表性早期和晚期鼻咽癌病例,比较国家方案HN001与本勾画策略的剂量学差异。
  • 主要终点为失败模式与局部控制,次要终点包括区域控制和生存,采用Kaplan-Meier法估计。

主要发现

  • 1999年至2013年共73例患者(88%为3-4期疾病),存活患者中位随访90个月,大体肿瘤体积中位剂量70 Gy。
  • 4例出现局部复发,1例出现区域复发;所有局部区域复发均位于高剂量大体肿瘤体积内。
  • 5年局部控制率为94%(95%CI 85%-98%),区域控制率为99%(95%CI 90%-100%),总生存率为84%(95%CI 73%-91%)。
  • 与HN001相比,本勾画策略使T1期临床靶区体积减少62%,T4期减少36%。
  • T1期肿瘤中,对侧腮腺、视神经和耳蜗剂量分别降低54%、50%和34%;T4期病例中,视交叉剂量降低46%,对侧视神经剂量降低37%。

临床怎么用

  • 作者基于长期经验认为,基于逐步扩散模式的个体化临床靶区勾画可获得良好局部控制,且无大体肿瘤体积外复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation-related toxicity in nasopharyngeal carcinoma (NPC) is common. There are no well-established guidelines for clinical target volume (CTV) delineation with long-term follow-up. Current consensus continues to rely heavily on bony landmarks and fixed margins around the gross tumor volume (GTV), an approach used to define fields in the conventional 2- and 3-dimensional radiation therapy era. METHODS AND MATERIALS: We retrospectively evaluated patients with newly diagnosed nonmetastatic NPC treated with definitive radiation therapy using a technique of CTV delineation based on individual tumor extent and the orderly stepwise pattern of tumor spread. Dosimetric comparisons were made between national protocol HN001 and our contouring strategies on a representative early- and advanced-stage NPC. The primary endpoints were patterns of failure and local control; secondary endpoints included regional control and survival, estimated using the Kaplan-Meier method. RESULTS: Between 1999 and 2013, 73 patients (88% with stage 3-4 disease) were treated with median follow-up of 90 months for surviving patients. Median dose to GTV was 70 Gy. Four patients developed local recurrence and 1 patient developed regional recurrence. All locoregional recurrences occurred within the high-dose GTV. The 5-year local control, regional control, and overall survival was 94% (95% confidence interval [CI], 85%-98%), 99% (95% CI, 90%-100%), and 84% (95% CI, 73%-91%), respectively. Compared with HN001, our contouring strategy resulted in 62% and 36% reduction in CTV for T1 and T4 disease, respectively. In the T1 tumor, the reduction of doses to the contralateral parotid, optic nerve, and cochlea were 54%, 50%, 34% respectively. In the T4 case, there was a decrease of optic chiasm dose of 46% and contralateral optic nerve of 37%. There were 10 grade 3 toxicities. There was no grade 2 or higher xerostomia and no grade 4/5 toxicity. CONCLUSIONS: Our long-term experience with individualized CTV delineation based on stepwise patterns of spread results in excellent local control, with no recurrence outside the GTV.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sanford NN, Lau J, Lam MB, et al. Individualization of Clinical Target Volume Delineation Based on Stepwise Spread of Nasopharyngeal Carcinoma: Outcome of More Than a Decade of Clinical Experience. Int J Radiat Oncol Biol Phys. 2018. PMID: 30712708. doi:10.1016/j.ijrobp.2018.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。